Skip to main content

Kiora Pharmaceuticals, Inc.

corporate_fare Company Profile

Kiora Pharmaceuticals, Inc.

KPRX·NASDAQ·Life Sciences·CIK 0001372514

The company is a clinical-stage specialty pharmaceutical company focused on developing and commercializing treatments for retinal diseases. Its primary development candidate is KIO-301, a potential vision-restoring small molecule designed to act as a "photoswitch" to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). An initial focus for KIO-301 is on patients with later stages of vision loss due to RP. The company completed a Phase 1b clinical trial for KIO-301 in September 2023 and presented topline results in November 2023. In January 2024, the company partnered with Théa Open Innovation (TOI). In October 2024, regulatory approval was received to initiate a Phase 2 clinical trial, named ABACUS-2, for KIO-301 in patients with RP. The ABACUS-2 trial is a 36-patient, multicenter, double-masked, randomized, controlled, multiple-dose study enrolling patients with ultra-low vision or no light perception, regardless of their underlying gene mutation associated with RP. Enrollment in the ABACUS-2 trial is currently ongoing. KIO-301, formerly known as B-203, was acquired through the Bayon Therapeutics, Inc. transaction, which closed on October 21, 2021. The company is also developing KIO-104 for retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery.

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KPRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for KPRX spans 10-Q, 8-K, 424B3, S-3.

Recent high-impact activity:

  • Kiora Q3 10-Q: Going-Concern Warning, $6.2M Nine-Month Loss, KIO-104 Shelved
  • Kiora In-Licenses Phase 3-Ready CRAO Drug KIO-401 for $3.5M Upfront, Up to $168.5M Milestones
  • Kiora Licenses KIO-301 South Korea Rights to CKD for $1M Upfront
  • Kiora Q2 2026: $16.8M Cash, Runway into Late 2028, and Clinical Momentum
  • Kiora Reports Positive Preclinical Data for KIO-300 in Epilepsy Model, Expanding Platform Potential

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$10.84M
Diluted EPS
-$2.64
Op. Cash Flow
-$9.96M
Free Cash Flow
-$10.07M
Operating Income
-$12.83M
Cash & Equivalents
$8.7M
Debt / Equity
0.00×
Shares Outstanding
3.76M sh
Source: 10-K · filed 2026-03-25 · accession 0001372514-26-000024

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 56,588 shares in KPRX as of the October 30, 2026 settlement, a 1248.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 17.9% of KPRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)56,588 shares as of October 30, 2026
Change vs prior period▲ 1248.6%
Days to cover1.00 at avg daily volume of 67,008
Daily short volume (FINRA facilities)17.9% of 9,822 shares on November 19, 2026
5-day average short volume19.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for KPRX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-28.

Massive Potential Dilution · No Direct Company Proceeds from Resale

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with K →
$0.7346 +2.00% today
52-week range · as of 2026-11-12 $0.7346 – $2.91
Market cap
$3.19M
Volume
64.7K (1.1× avg)
3-mo avg 59.8K
Live data · 2026-11-20 22:11 UTC · After hours

show_chartPrice Chart

Loading chart...

feed KPRX - Latest Insights

KPRX
Nov 12, 2026, 7:01 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $0.7346 info
Change: -$0.6654 (-48%) info
Market Cap: $3.186M info
KPRX
Oct 29, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.58
Real-time Price: $0.7346 info
Change: -$1.85 (-72%) info
Market Cap: $3.186M info
KPRX
Aug 19, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $0.7346 info
Change: -$1.92 (-72%) info
Market Cap: $3.186M info
KPRX
Aug 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.58
Real-time Price: $0.7346 info
Change: -$1.85 (-72%) info
Market Cap: $3.186M info
KPRX
Jun 18, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $0.7346 info
Change: -$1.84 (-71%) info
Market Cap: $3.186M info
KPRX
Jun 18, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $0.7346 info
Change: -$1.84 (-71%) info
Market Cap: $3.186M info
KPRX
Jun 10, 2026, 6:39 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.58
Real-time Price: $0.7346 info
Change: -$1.85 (-72%) info
Market Cap: $3.186M info
KPRX
May 28, 2026, 5:28 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $2.83
Real-time Price: $0.7346 info
Change: -$2.10 (-74%) info
Market Cap: $3.186M info
KPRX
May 18, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $2.51
Real-time Price: $0.7346 info
Change: -$1.78 (-71%) info
Market Cap: $3.186M info
KPRX
May 08, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.43
Real-time Price: $0.7346 info
Change: -$1.70 (-70%) info
Market Cap: $3.186M info
KPRX
May 08, 2026, 7:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.43
Real-time Price: $0.7346 info
Change: -$1.70 (-70%) info
Market Cap: $3.186M info
KPRX
May 08, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $2.43
Real-time Price: $0.7346 info
Change: -$1.70 (-70%) info
Market Cap: $3.186M info
KPRX
Apr 30, 2026, 5:11 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $0.7346 info
Change: -$1.62 (-69%) info
Market Cap: $3.186M info
KPRX
Apr 07, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.91
Real-time Price: $0.7346 info
Change: -$1.18 (-62%) info
Market Cap: $3.186M info
KPRX
Apr 02, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $0.7346 info
Change: -$1.29 (-64%) info
Market Cap: $3.186M info
KPRX
Mar 25, 2026, 7:01 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.06
Real-time Price: $0.7346 info
Change: -$1.33 (-64%) info
Market Cap: $3.186M info
KPRX
Mar 25, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
9
Price at Filing: $2.06
Real-time Price: $0.7346 info
Change: -$1.33 (-64%) info
Market Cap: $3.186M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets